Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
Jessica C. Hassel, Carola Berking, Andrea Forschner, et al.
European Journal of Cancer (2023) Vol. 191, pp. 112986-112986
Open Access | Times Cited: 17

Showing 17 citing articles:

Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
Arthur Géraud, Thomas Hueso, Ariane Laparra, et al.
European Journal of Cancer (2024) Vol. 205, pp. 114075-114075
Closed Access | Times Cited: 9
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Jacob Sands, Stéphane Champiat, H.-D. Hummel, et al.
Cancer (2025) Vol. 131, Iss. 3
Open Access | Times Cited: 1
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma
Robin Reschke, Alexander Enk, Jessica C. Hassel
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1046-1046
Open Access | Times Cited: 6
Targeted therapy in ophthalmic oncology: The current status
Mrittika Sen, Hakan Demirci, Santosh G Honavar
Asia-Pacific Journal of Ophthalmology (2024) Vol. 13, Iss. 2, pp. 100062-100062
Open Access | Times Cited: 5
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Elias A. T. Koch, Markus V. Heppt, Carola Berking
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 5, pp. 691-700
Open Access | Times Cited: 3
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy
A. C. Chiang, M.E. Olmedo García, Jennifer W. Carlisle, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104538-104538
Open Access
Targeted theranostic nanomedicine using targeted CT-imageable particles that release tebentafusp.
Satoshi Harada, Takahiro Sato, Katsunari Yoshioka
Japanese Journal of Radiology (2025)
Open Access
Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action
Jessica C. Hassel, Sarah Stanhope, Alexander Greenshields‐Watson, et al.
Journal of Investigative Dermatology (2024)
Open Access | Times Cited: 3
Engineered T cells for Colorectal Cancer
Nurul Ainaa Adilah Rus Bakarurraini, Ammar Akram Kamarudin, Rahman Jamal, et al.
Immunotherapy (2024) Vol. 16, Iss. 14-15, pp. 987-998
Closed Access | Times Cited: 2
Clinical and pathological characterization of Tebentafusp-associated skin toxicity – a cohort study with 33 patients.
Dirk Tomsitz, Katrin Kerl, Lars E. French, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1136-1142
Open Access | Times Cited: 1
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, et al.
Current Drug Targets (2023) Vol. 25, Iss. 3, pp. 149-157
Closed Access | Times Cited: 2
Drug-related exanthema under immunotherapy and targeted oncological therapy
Mirjana Ziemer, Elisabeth Livingstone
Deleted Journal (2024) Vol. 75, Iss. 6, pp. 440-450
Closed Access
Nebenwirkungen dermatoonkologischer Therapien
Jessica C. Hassel, Lisa Zimmer
Deleted Journal (2024) Vol. 75, Iss. 6, pp. 466-475
Closed Access
Häufigster okkulärer Tumor des Erwachsenen: Diagnostik und Therapie des Aderhautmelanoms
Sebastian Ochsenreither, M. de Bucourt, Oliver Zeitz, et al.
Trillium Krebsmedizin (2024) Vol. 33, Iss. 3, pp. 198-203
Closed Access
Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer
Jacob Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Insights into ocular cancer oncogenesis (Review)
Ravi Parashar, Anju Dewangan, Kuldeep Singh Thakur, et al.
World Academy of Sciences Journal (2024) Vol. 7, Iss. 2
Open Access
Sepsis‐like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma
Glenn Geidel, Finn Abeck, Inga Hansen, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 6
Closed Access | Times Cited: 1
Page 1

Scroll to top